Goldman Sachs’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-837,602
| Closed | -$7.56M | – | 7022 |
|
|
2025
Q4 | $7.56M | Buy |
837,602
+430,691
| +106% | +$3.22M | ﹤0.01% | 3354 |
|
|
2025
Q3 | $1.27M | Sell |
406,911
-173,453
| -30% | -$460K | ﹤0.01% | 4869 |
|
|
2025
Q2 | $1.24M | Sell |
580,364
-12,884
| -2% | -$20.8K | ﹤0.01% | 4536 |
|
|
2025
Q1 | $682K | Sell |
593,248
-917,509
| -61% | -$1.58M | ﹤0.01% | 4980 |
|
|
2024
Q4 | $3.31M | Sell |
1,510,757
-424,273
| -22% | -$961K | ﹤0.01% | 3853 |
|
|
2024
Q3 | $4.22M | Buy |
1,935,030
+475,899
| +33% | +$1.09M | ﹤0.01% | 3491 |
|
|
2024
Q2 | $3.37M | Sell |
1,459,131
-224,957
| -13% | -$935K | ﹤0.01% | 3518 |
|
|
2024
Q1 | $9.26M | Buy |
1,684,088
+321,299
| +24% | +$1.47M | ﹤0.01% | 2532 |
|
|
2023
Q4 | $3.37M | Sell |
1,362,789
-252,757
| -16% | -$2.4M | ﹤0.01% | 3502 |
|
|
2023
Q3 | $56.1M | Buy |
1,615,546
+47,726
| +3% | +$1.65M | 0.01% | 1036 |
|
|
2023
Q2 | $51.4M | Buy |
1,567,820
+217,280
| +16% | +$7.49M | 0.01% | 1077 |
|
|
2023
Q1 | $45.2M | Buy |
1,350,540
+1,304,211
| +2,815% | +$50.7M | 0.01% | 1138 |
|
|
2022
Q4 | $1.52M | Buy |
46,329
+22,086
| +91% | +$654K | ﹤0.01% | 4140 |
|
|
2022
Q3 | $846K | Buy |
24,243
+5,375
| +28% | +$119K | ﹤0.01% | 4624 |
|
|
2022
Q2 | $231K | Buy |
+18,868
| New | +$282K | ﹤0.01% | 5574 |
|
Other funds holding VTYX
Goldman Sachs's VTYX Position: Q1 2026 in Review
Goldman Sachs sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 837,602 shares — an estimated $7.56M sold.
Goldman Sachs first reported a position in VTYX in Q2 2022 and held it in 15 quarters. The position peaked at $56.1M in Q3 2023. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- Goldman Sachs reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- Goldman Sachs sold 837,602 Ventyx Biosciences shares in Q1 2026, an estimated $7.56M.
- Goldman Sachs first reported a position in Ventyx Biosciences in Q2 2022 and held it in 15 quarters.
- Goldman Sachs's Ventyx Biosciences position peaked at $56.1M in Q3 2023.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.